AI assistant
PolyPid Ltd. — Foreign Filer Report 2024
Jun 18, 2024
34543_ffr_2024-06-18_e119ce38-6917-44cf-8604-5458466f571d.zip
Foreign Filer Report
Open in viewerOpens in your device viewer
6-K 1 ea0207991-6k_polypid.htm REPORT OF FOREIGN PRIVATE ISSUER
Field: Rule-Page
Field: /Rule-Page
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of: June 2024
Commission File Number: 001-38428
PolyPid Ltd.
(Translation of registrant’s name into English)
18 Hasivim Street
Petach Tikva 495376, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
☒ Form 20-F ☐ Form 40-F
Field: Rule-Page
Field: /Rule-Page
Field: Page; Sequence: 1
Field: /Page
CONTENTS
Attached hereto and incorporated herein is PolyPid Ltd.’s (the “Registrant”) press release issued on June 18, 2024, titled “PolyPid Hosts KOL Call to Discuss Significant Unmet Medical Need in Surgical Site Infections Prevention and Provides Update on its Ongoing SHIELD II Phase 3 Trial.”
The first, second and fourth paragraphs and the section titled “Forward-looking Statements” in the press release are incorporated by reference into the Registrant’s registration statements on Form F-3 (File No. 333-257651 and File No. 333-276826 ) and Form S-8 (File No. 333-239517 , File No. 333-271060 , and File No. 333-277703 ), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
Field: Page; Sequence: 2; Options: NewSection; Value: 1
Field: Sequence; Type: Arabic; Name: PageNo 1 Field: /Sequence
Field: /Page
EXHIBIT INDEX
| Exhibit No. | |
|---|---|
| 99.1 | Press |
| Release issued by PolyPid Ltd. on June 18, 2024, titled “PolyPid Hosts KOL Call to Discuss Significant Unmet Medical Need in | |
| Surgical Site Infections Prevention and Provides Update on its Ongoing SHIELD II Phase 3 Trial.” |
Field: Page; Sequence: 3; Value: 1
Field: Sequence; Type: Arabic; Name: PageNo 2 Field: /Sequence
Field: /Page
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| /s/ Dikla Czaczkes Akselbrad | |
|---|---|
| Name: | Dikla Czaczkes Akselbrad |
| Title: | Chief Executive Officer |
3
Field: Rule-Page
Field: /Rule-Page